Per SDC, added redirection to posaconazole for mucormycosis and aspergillosis if member is age ≥ 13 years and had prior inadequate response (i.e., refractory or progressive aspergillosis) to voriconazole
HIM.PA.SP60
Biologic and Non-biologic DMARDs
03/01/2026
Per August SDC: for PsO, PsA, CD, and UC initial approval criteria, added redirection to additional preferred ustekinumab products (Pyzchiva, Steqeyma, and Yesintek) and applied to continuation of therapy requests, and for members initiating therapy with Stelara added a single step through preferred agents; for RA, pJIA, PsA, AS, CD, UC, PsO, HS, UV initial therapy, added redirection to preferred adalimumab products (adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, Simlandi) and removed redirection to Cyltezo; for members initiating therapy with Humira initial approval criteria, added single step through preferred agents; extended initial approval durations from 6 months to 12 months for chronic indications.
For questions about QualChoice Medical Coverage Policies, please contact your Provider Relations Representative at 800.235.7111 or 501.228.7111, Monday through Friday, 8:00 a.m. to 5:00 p.m.
